Halozyme Therapeutics (HALO) vs. Harpoon Therapeutics (HARP) Head-To-Head Contrast
Halozyme Therapeutics (NASDAQ:HALO) and Harpoon Therapeutics (NASDAQ:HARP) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, dividends, valuation and profitability.
Insider & Institutional Ownership
82.6% of Halozyme Therapeutics shares are owned by institutional investors. 14.1% of Halozyme Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This is a breakdown of recent ratings and recommmendations for Halozyme Therapeutics and Harpoon Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Halozyme Therapeutics currently has a consensus price target of $20.40, suggesting a potential upside of 26.87%. Harpoon Therapeutics has a consensus price target of $23.50, suggesting a potential upside of 94.86%. Given Harpoon Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Harpoon Therapeutics is more favorable than Halozyme Therapeutics.
This table compares Halozyme Therapeutics and Harpoon Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Halozyme Therapeutics and Harpoon Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Halozyme Therapeutics||$151.86 million||15.36||-$80.33 million||($0.56)||-28.71|
Harpoon Therapeutics has lower revenue, but higher earnings than Halozyme Therapeutics.
Harpoon Therapeutics beats Halozyme Therapeutics on 6 of the 9 factors compared between the two stocks.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc., a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. The company's products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its pipeline include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs in subcutaneous urography; and to enhance resorption of radiopaque agents. The company also develops PEGPH20, a therapy that is in Phase III clinical trial for pancreatic ductal adenocarcinoma; in Phase Ib clinical trial for non-small cell lung cancer; in Phase Ib/II clinical trial for patients with previously treated metastatic pancreatic ductal adenocarcinoma; in Phase Ib/II clinical trial for patients with gastric cancer; and in Phase Ib/II for cholangiocarcinoma and gall bladder cancer. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; and ARGENX BVBA. The company was founded in 1998 and is headquartered in San Diego, California.
Harpoon Therapeutics Company Profile
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. It is involved in developing HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer; and HPN536 for the treatment of ovarian cancer and other mesothelin expressing tumors, as well as other products targeting tumor-associated antigens for the treatment of multiple myeloma and small-cell lung cancer. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.